Cate Lockhart, PharmD, PhD, discusses when she believes the industry will start seeing biosimilars driving down cost of drugs.
Transcript
When will we see price competition on biosimilars?
I think if you think of it in a purely economic, capitalistic sense then you should expect, like [with] generics, with 3 [biosimilars on the market] it’s enough competition to bring that down. But, again, there’s other considerations in predicting how much of an impact that will [have]. In Europe they are seeing significant costs and influences, but they also have multiple products per category, for the most part, and they have a healthcare structure that’s quite a bit different and quite a bit more linear and a bit simpler than what we face in the United States. Here, there’s contracting and rebates, and all of these other components that go into pricing that I think becomes more of a challenge and harder to predict. At least my perspective is that you really have to think more broadly, you have to think longitudinally and not quarterly, “This is my bottom line this quarter,” but looking more longitudinally about say, [if] I’m a payer or a physician, ultimately, what’s going to be the best for the patients, including their costs as well as their treatment.
Now if we assume, like we’re saying that biosimilars really are clinically no different, then thinking about some of those other considerations is important for our patients. Again, it comes down to having evidence to support that, to trust the biosimilars.
Q&A With Dr Chelsee Jensen: Navigating FDA Approvals, Challenges in the Biosimilar Landscape
January 14th 2024Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist and pharmaceutical formulary manager at Mayo Clinic, reacts to the biggest FDA approvals of 2023 and how she sees the adalimumab, natalizumab, and tocilizumab spaces playing out.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
IGBA 2023: Dr Monique Mansoura Highlights the Intersection of Geopolitical Issues, Biopharma
February 19th 2023COVID-19 allowed governments to critically examine the biopharma space to increase access to vaccines, but there's still a way to go, according to Monique Mansoura, PhD, MBA, executive director of global health security and biotechnology at the MITRE Corporation, at the International Generic and Biosimilar Medicines Association’s annual meeting.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.